Victoria A. Matyushenko

Victoria A. Matyushenko

Auto-generated profile, based on publicly available information

Victoria A. Matyushenko

Institute of Experimental Medicine

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
LRLarisa G. Rudenko
Larisa G. Rudenko
IIIrina Isakova-Sivak
Irina Isakova-Sivak
ANAnatoly Naykhin
Anatoly Naykhin
Irina KiselevaIrina Kiseleva
Irina Kiseleva
SMStukova Marina
Stukova Marina
MKMarie-Paule Kieny
Marie-Paule Kieny

1 May 2018 in Virology
Verified
Journal Article
Closed access
IIIrina Isakova-Sivak
Irina Isakova-Sivak
DKDaniil Korenkov
Daniil Korenkov
TSTatiana Smolonogina
Tatiana Smolonogina
TKTatiana Kotomina
Tatiana Kotomina
SDSvetlana Donina
Svetlana Donina
LRLarisa Rudenko
Larisa Rudenko

29 August 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
TKTatiana Kotomina
Tatiana Kotomina
DKDaniil Korenkov
Daniil Korenkov
VMVictoria Matyushenko
Victoria Matyushenko
PPPolina Prokopenko
Polina Prokopenko
LRLarisa G. Rudenko
Larisa G. Rudenko
IIIrina Isakova-Sivak
Irina Isakova-Sivak
The development of viral vector vaccines against various pathogens for which conventional vaccination approaches are not applicable has been a priority for a number of years. One promising approach is the insertion of immunodominant conservative cytotoxic T-cell (CTL) epitopes into the genome of a viral vector, which then delivers these epitopes to target cells, inducing immunity. Many different viruses have been assessed as viral vectors for CTL-based vaccines, but only a few of them are clinically relevant, mainly because of safety issues and limited knowledge about their performance in humans. In this regard, the use of licensed cold-adapted live attenuated influenza vaccine (LAIV) viruses as a vector delivery system has clear advantages for CTL-based vector vaccines against other respiratory pathogens: LAIV is known to induce all arms of the adaptive immune system and is administered via nasal spray, and its production process is relatively easy and inexpensive. Here we present the first results of the use of an LAIV backbone for designing a CTL epitope-based vaccine against respiratory syncytial virus (RSV). The chimeric LAIV-RSV vaccine candidates were attenuated in mice and induced strong, fully functional CTL immunity in this animal model.

7 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VMVictoria Matyushenko
Victoria Matyushenko
IIIrina Isakova-Sivak
Irina Isakova-Sivak
TSTatiana Smolonogina
Tatiana Smolonogina
IDIrina Dubrovina
Irina Dubrovina
TTTatiana Tretiak
Tatiana Tretiak
LRLarisa Rudenko
Larisa Rudenko
Live attenuated influenza vaccines (LAIVs) are considered as safe and effective tool to control influenza in different age groups, especially in young children. An important part of the LAIV safety evaluation is the detection of vaccine virus replication in the nasopharynx of the vaccinees, with special attention to a potential virus transmission to the unvaccinated close contacts. Conducting LAIV clinical trials in some geographical regions with year-round circulation of influenza viruses warrants the development of robust and reliable tools for differentiating vaccine viruses from wild-type influenza viruses in nasal pharyngeal wash (NPW) specimens of vaccinated subjects. Here we report the development of genotyping assay for the detection of wild-type and vaccine-type influenza virus genes in NPW specimens of young children immunized with Russian-backbone seasonal trivalent LAIV using Sanger sequencing from newly designed universal primers. The new primer set allowed amplification and sequencing of short fragments of viral genes in NPW specimens and appeared to be more sensitive than conventional real-time RT-PCR protocols routinely used for the detection and typing/subtyping of influenza virus in humans. Furthermore, the new assay is capable of defining the origin of wild-type influenza virus through BLAST search with the generated sequences of viral genes fragments.

1 August 2016 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
IIIrina Isakova-Sivak
Irina Isakova-Sivak
DKD. A. Korenkov
D. A. Korenkov
EFE. A. Fedorova
E. A. Fedorova
TTT. S. Tretiak
T. S. Tretiak
VMV. A. Matyushenko
V. A. Matyushenko
LRL. G. Rudenko
L. G. Rudenko

16 December 2025 in Cytokines and inflammation
Verified
Journal Article
Open access
PDF file
ELElena V. Litasova
Elena V. Litasova
VMVictoria A. Matyushenko
Victoria A. Matyushenko
Alexey SokolovAlexey Sokolov
Alexey Sokolov
DMDaria Mezhenskaya
Daria Mezhenskaya
LMLeonid V. Myznikov
Leonid V. Myznikov
МАМеженская Дарья Андреевна
Меженская Дарья Андреевна
BACKGROUND: Transferrin receptor 1 (TfR1, CD71) is a multifunctional protein important for maintaining cellular iron homeostasis by binding to the main iron transporter transferrin (Tf). In addition to Tf, it can bind and transfer proteins, viruses, chemotherapeutic agents, and other biomolecules to the cell. Ferristatin II, a TfR1 degradation inducer, has previously been shown to inhibit SARS-CoV-2 infection in Vero cells; however, this agent cannot be used as a medicinal product, because its metabolism produces carcinogenic benzidine derivatives. AIM: To assess the antiviral activity of specific azo compounds (structural analogs of ferristatin II) to identify common structural patterns of compounds that are the most effective against SARS-CoV-2. The findings will be used to develop safer antiviral analogs of ferristatin II. METHODS: The paper investigates the antiviral activity of 15 compounds, including 5 de novo compounds generated by organic synthesis. The antiviral activity of the drugs was evaluated by their ability to inhibit the replication of SARS-CoV-2 Delta in Vero cell culture. Cytotoxicity of the compounds for this cell line was determined by the MTS assay. Additionally, the ability of the most effective compounds to inhibit iron uptake by Vero cells was assessed using the HMRhoNox-M chemosensor. RESULTS: In the studied stains similar to ferristatin II, direct black (average inhibitory concentration IC50 = 53.7 μM), direct green (IC50 = 53.6 μM), direct diazo black C (IC50 = 28.2 μM), and direct black 2K (IC50 = 45.3 μM) inhibited the viral activity. In addition, direct green showed pronounced toxicity to Vero cells (CC50 = 29.1 μM); whereas none of the black dyes showed cytotoxicity at a highest concentration of 200 μM. The recorded decrease in viral replication in the presence of the drugs correlated with the reduced ability of Vero cells to capture iron, indicating the involvement of TfR1 in the antiviral activity of direct azo stains. CONCLUSION: The study identified general patterns of direct azo dyes that are most active against SARS-CoV-2, i.e. approximately four acidic groups (sulfo groups) at the ends of the molecule and a small rigid flat linker (benzidine) connecting them. The findings open up prospects for the development of safe analogs of ferristatin II. In particular, benzidine may be replaced with less toxic tetramethylbenzidine and diaminoanthraquinone to reduce carcinogenic activity; to improve the structure, we propose to replace the sulfo groups with carboxyl groups.